Publications
Detailed Information
Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, In Sil | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Kim, Ki Hwan | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.date.accessioned | 2012-06-27T06:50:32Z | - |
dc.date.available | 2012-06-27T06:50:32Z | - |
dc.date.issued | 2010-09 | - |
dc.identifier.citation | MEDICAL ONCOLOGY; Vol.27 3; 992-997 | ko_KR |
dc.identifier.issn | 1357-0560 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77613 | - |
dc.description.abstract | Combination chemotherapy of S-1 and cisplatin has shown promising activity against advanced gastric cancer, but the schedules and dose intensities of S-1 and cisplatin have not been consistent in several clinical trials. We investigated the efficacy and toxicity of 3-weekly S-1/cisplatin chemotherapy as first-line treatment in metastatic or relapsed gastric cancer (MRGC). Forty-six patients with MRGC were prospectively enrolled. S-1 (80 mg/m(2)/day; days 1-14) and cisplatin (60 mg/m(2); day 1) were administrated every 3 weeks. Among 46 patients who received chemotherapy, one achieved a complete response and 21 achieved a partial response, resulting in an overall response rate (RR) of 48%. Thirteen patients (28%) had stable disease and eight patients (17%) had progressive disease. After a median follow-up duration of 48.3 weeks, the median progression-free survival (PFS) and overall survival (OS) were 21.1 weeks and 68.3 weeks, respectively. Patients with good Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1 had prolonged PFS and OS compared with patients with ECOG PS of 2. Common hematologic toxicities were anemia (93%), leucopenia (61%), and neutropenia (61%). However, grade 3/4 anemia, leucopenia, and neutropenia developed in only 11, 9, and 24% of patients, respectively. Grade 3/4 non-hematologic toxicities included anorexia (22%), fatigue (13%), nausea (7%), and diarrhea (7%). No treatment-related mortality occurred. Three-weekly S-1/cisplatin chemotherapy was active and well-tolerated in MRGC patients. | ko_KR |
dc.description.sponsorship | This study was partially supported by grants
from Korean Cancer Research Foundation, Seoul National University Bundang Hospital Research Fund (11-2008-034), and Seoul Municipal Boramae Hospital Clinical Research Fund. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | HUMANA PRESS INC | ko_KR |
dc.subject | S-1 | ko_KR |
dc.subject | Gastric cancer | ko_KR |
dc.subject | Cisplatin | ko_KR |
dc.subject | Chemotherapy | ko_KR |
dc.title | Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 최인실 | - |
dc.contributor.AlternativeAuthor | 이근욱 | - |
dc.contributor.AlternativeAuthor | 김기환 | - |
dc.contributor.AlternativeAuthor | 김유정 | - |
dc.contributor.AlternativeAuthor | 김지현 | - |
dc.contributor.AlternativeAuthor | 이종석 | - |
dc.identifier.doi | 10.1007/s12032-009-9321-x | - |
dc.citation.journaltitle | MEDICAL ONCOLOGY | - |
dc.description.citedreference | Kang YK, 2009, ANN ONCOL, V20, P666, DOI 10.1093/annonc/mdn717 | - |
dc.description.citedreference | Seo MD, 2008, JPN J CLIN ONCOL, V38, P589, DOI 10.1093/jjco/hyn078 | - |
dc.description.citedreference | Lee JL, 2008, CANCER CHEMOTH PHARM, V61, P837, DOI 10.1007/s00280-007-0541-5 | - |
dc.description.citedreference | Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI 10.1016/S1470-204S(08)70035-4 | - |
dc.description.citedreference | Cunningham D, 2008, NEW ENGL J MED, V358, P36 | - |
dc.description.citedreference | CHOI IS, 2007, CANC RES TREAT, V39, P99 | - |
dc.description.citedreference | Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429 | - |
dc.description.citedreference | Ajani JA, 2006, J CLIN ONCOL, V24, P663, DOI 10.1200/JCO.2005.04.2994 | - |
dc.description.citedreference | Lee KW, 2005, JPN J CLIN ONCOL, V35, P720, DOI 10.1093/jjco/hyi198 | - |
dc.description.citedreference | Ajani JA, 2005, J CLIN ONCOL, V23, P6957, DOI 10.1200/JCO.2005.01.917 | - |
dc.description.citedreference | Iwase H, 2005, ANTICANCER RES, V25, P1297 | - |
dc.description.citedreference | Koizumi W, 2003, BRIT J CANCER, V89, P2207, DOI 10.1038/sj.bjc.6601413 | - |
dc.description.citedreference | PARKIN DM, 2002, CA CANC J CLIN, V55, P74 | - |
dc.description.citedreference | Vanhoefer U, 2000, J CLIN ONCOL, V18, P2648 | - |
dc.description.citedreference | Koizumi W, 2000, ONCOLOGY-BASEL, V58, P191 | - |
dc.description.citedreference | Sakata Y, 1998, EUR J CANCER, V34, P1715 | - |
dc.description.citedreference | Glimelius B, 1997, ANN ONCOL, V8, P163 | - |
dc.description.citedreference | Shirasaka T, 1996, ANTI-CANCER DRUG, V7, P548 | - |
dc.description.citedreference | PYRHONEN S, 1995, BRIT J CANCER, V71, P587 | - |
dc.description.citedreference | MURAD AM, 1993, CANCER, V72, P37 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.